Baxter International (NYSE:BAX) Updates Q4 2024 Earnings Guidance

Baxter International (NYSE:BAXGet Free Report) updated its fourth quarter 2024 earnings guidance on Friday. The company provided earnings per share guidance of 0.770-0.810 for the period, compared to the consensus earnings per share estimate of 0.840. The company issued revenue guidance of -. Baxter International also updated its FY 2024 guidance to 2.900-2.940 EPS.

Baxter International Price Performance

Shares of NYSE BAX opened at $34.64 on Friday. The company has a 50 day simple moving average of $37.39 and a two-hundred day simple moving average of $36.12. Baxter International has a fifty-two week low of $32.48 and a fifty-two week high of $44.01. The company has a market capitalization of $17.67 billion, a price-to-earnings ratio of 7.13, a P/E/G ratio of 1.22 and a beta of 0.60. The company has a debt-to-equity ratio of 1.35, a quick ratio of 0.91 and a current ratio of 1.40.

Baxter International (NYSE:BAXGet Free Report) last posted its quarterly earnings data on Friday, November 8th. The medical instruments supplier reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The company had revenue of $3.85 billion during the quarter, compared to analyst estimates of $3.85 billion. During the same quarter last year, the company earned $0.68 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. Analysts expect that Baxter International will post 2.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on BAX shares. Wells Fargo & Company dropped their price target on shares of Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 7th. StockNews.com upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a report on Tuesday, October 22nd. Citigroup raised their price target on shares of Baxter International from $38.00 to $40.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. Morgan Stanley cut Baxter International from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $39.00 to $30.00 in a research report on Monday, July 15th. Finally, JPMorgan Chase & Co. reduced their target price on Baxter International from $44.00 to $42.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $41.20.

Read Our Latest Stock Analysis on Baxter International

About Baxter International

(Get Free Report)

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

Featured Articles

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.